# Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease

> **NCT07541391** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Peter MacCallum Cancer Centre, Australia** · enrollment: 12 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** PMCC-COE-KMA

## Key facts

- **NCT ID:** NCT07541391
- **Lead sponsor:** Peter MacCallum Cancer Centre, Australia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-09
- **Final completion:** 2030-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07541391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07541391, "Autologous Chimeric Antigen Receptor (CAR) T-cells Targeting the Kappa Myeloma Antigen (KMA) in Kappa Restricted Multiple Myeloma Patients With Relapsed/Refractory Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07541391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*